Old drug, new target: blood pressure pill tested against cancer
NCT ID NCT05797662
Summary
This study is testing whether propranolol, a common blood pressure and heart medication, can safely shrink tumors in people with Kaposi Sarcoma, a type of cancer. It will involve about 25 children and adults with early-stage disease who are not in urgent need of chemotherapy. Participants will take the pill twice daily for 12 weeks to see if their tumors respond, with the option to continue if they improve.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
African Cancer Institute at Stellenbosch
Cape Town, South Africa
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Complexo Hospitalar Universitário Professor Edgard Santos
Salvador, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundación Huésped
Buenos Aires, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Nacional de Cancerologia
Mexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Instituto Nacional de Câncer José de Alencar
Rio de Janeiro, 20231-050, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moi University School of Medicine
Eldoret, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UNC Project Malawi
Lilongwe, Malawi
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Uganda Cancer Institute
Kampala, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Zimbabwe College of Health Sciences
Harare, Zimbabwe
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.